FAK inhibitors have already been reported as potent anti-angiogenic agents and have been shown to reduce tumor angiogenesis in animal models of colon, ovarian, and hepatocellular carcinoma [62,65,66]. This evidence concerns the gene PTK2 and hepatocellular carcinoma.